A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.
Relapsed or Refractory B-cell Malignancy(NHL/ALL)
BIOLOGICAL: ET-02
Incidence of adverse events, Adverse events assessed according to NCI-CTCAE v5.0 criteria, up to 2 years after lymphodepleting chemotherapy
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.